Immutep (Prima Biomed) | PRR | Pharmaceuticals & biotechnology
Performance | Valuation | Growth | Summary | Balance Sheet | Income Statement | Cash Flow
A$ in Million. Fiscal year ends in June. Figures are consolidated and restated.
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | ||
Cash flow Operating Act... |  | -6 | -10 | -19 | -16 | -14 | -8 | -11 | -9 |
Investments in PPE | | -0.1 | -0.04 | -0.57 | -0.51 | -0.1 | -0.05 | -0.03 | -0.01 |
Cash flow Investing Act... | | 0 | 0 | -12 | 13 | -1 | -12 | 0.1 | -0.01 |
Cash flow Financing Act... | | 21 | 50 | 2 | 7 | 7 | 11 | 26 | -0.01 |
Cash at beginning of period | | 0.94 | 6 | 46 | 17 | 22 | 14 | 7 | 21 |
Cash at end of period | | 6 | 46 | 17 | 22 | 14 | 7 | 21 | 12 |
Free Cash Flow | | -7 | -10 | -20 | -17 | -14 | -8 | -11 | -9 |